Education
About Us
Working with TipRanks
Follow Us
Xbrane Biopharma AB (SE:XBRANE)
:XBRANE
XBRANE Stock Chart & Stats
kr10.37
>-kr0.01(-2.10%)
At close: 4:00 PM EST
kr10.37
>-kr0.01(-2.10%)
Day’s Range― - ―
52-Week Rangekr5.62 - kr38.33
Previous CloseN/A
Volume1.93M
Average Volume (3M)117.17K
Market Cap
kr123.84M
Enterprise Valuekr44.89M
Total Cash (Recent Filing)kr86.59M
Total Debt (Recent Filing)kr58.31M
Price to Earnings (P/E)122.0
Beta0.91
Next Earnings
May 05, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding20,605,349
10 Day Avg. Volume189,097
30 Day Avg. Volume117,165
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)27.69
Price to Sales (P/S)101.88
P/FCF Ratio-61.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.14
Revenue Forecast (FY)kr186.50M
Bulls Say, Bears Say
Bulls Say
Balance Sheet ImprovementThe 2025 capital structure shows materially lower debt and much higher equity, reducing leverage and near-term refinancing pressure. A stronger balance sheet improves runway and bargaining power with partners, supporting program advancement and strategic optionality over coming quarters.
Partnership/licensing Revenue ModelXbrane’s business model emphasizes out-licensing and partnerships that can deliver non-dilutive upfronts, milestones and royalties. This structure de-risks development spending, aligns incentives with commercial partners, and provides durable potential cash inflection points if programs progress.
In-house Biologics Development & ManufacturingOwning development and manufacturing capabilities is a structural competitive advantage in biosimilars: it supports tech transfer, lowers partner execution risk, enables contract services revenue, and can improve gross margins and partner attractiveness over the medium term.
Bears Say
Persistent Negative Cash FlowConsistent and deep negative operating and free cash flows mean the company cannot self-fund development. Ongoing cash burn heightens dependence on external financing or partner payments, increasing dilution and execution risk for program advancement over the next several quarters.
Sustained Operating LossesOperating results remain structurally loss-making, with negative EBIT/EBITDA across reported years. The 2025 positive net income appears driven by non-operating items, so core profitability has not been demonstrated, limiting ability to build internally funded growth.
Revenue Volatility And Recent DeclineRevenue growth has been uneven and recently contracted materially, which increases forecasting uncertainty and weakens predictable milestone/royalty timing. This volatility complicates partner negotiations and heightens execution risk for sustaining development and commercialization plans.
Xbrane Biopharma AB News
XBRANE FAQ
What was Xbrane Biopharma AB’s price range in the past 12 months?
Xbrane Biopharma AB lowest stock price was kr5.62 and its highest was kr38.33 in the past 12 months.
What is Xbrane Biopharma AB’s market cap?
Xbrane Biopharma AB’s market cap is kr123.84M.
When is Xbrane Biopharma AB’s upcoming earnings report date?
Xbrane Biopharma AB’s upcoming earnings report date is May 05, 2026 which is in 50 days.
How were Xbrane Biopharma AB’s earnings last quarter?
Xbrane Biopharma AB released its earnings results on Feb 20, 2026. The company reported -kr1.28 earnings per share for the quarter, beating the consensus estimate of -kr1.49 by kr0.21.
Is Xbrane Biopharma AB overvalued?
According to Wall Street analysts Xbrane Biopharma AB’s price is currently Overvalued.
Does Xbrane Biopharma AB pay dividends?
Xbrane Biopharma AB does not currently pay dividends.
What is Xbrane Biopharma AB’s EPS estimate?
Xbrane Biopharma AB’s EPS estimate is -0.52.
How many shares outstanding does Xbrane Biopharma AB have?
Xbrane Biopharma AB has 20,605,349 shares outstanding.
What happened to Xbrane Biopharma AB’s price movement after its last earnings report?
Xbrane Biopharma AB reported an EPS of -kr1.28 in its last earnings report, beating expectations of -kr1.49. Following the earnings report the stock price went down -13.017%.
Which hedge fund is a major shareholder of Xbrane Biopharma AB?
Currently, no hedge funds are holding shares in SE:XBRANE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xbrane Biopharma AB
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.
Technical Analysis
Ascelia Pharma AB
―
Intervacc AB
―
Guard Therapeutics International AB
―
Active Biotech AB
―
Immunicum AB
―